Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study
- Resource Type
- Authors
- Laura Martinez Valenzuela; Marian Goicoechea; Clara Maria Cases Corona; Javier Carbayo; Ana Huerta; Natalia Ramos Terrada; Tamara Gelen Malek-Marín; Amir Shabaka; Anna Pocurull; Ana Pérez de José; Loreto Fernandez Lorente; Teresa Bada-Bosch
- Source
- Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Clinical Kidney Journal
- Subject
- hepatitis C virus
medicine.medical_specialty
direct-acting antiviral agents
membranoproliferative glomerulonephritis
Hepatitis C virus
cryoglobulinaemia
Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic [DISEASES]
medicine.disease_cause
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Interquartile range
Internal medicine
Medicine
Other subheadings::/therapeutic use [Other subheadings]
AcademicSubjects/MED00340
Medicaments antivírics - Ús terapèutic - Eficàcia
030304 developmental biology
virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]
0303 health sciences
Transplantation
Kidney diseases
Otros calificadores::/uso terapéutico [Otros calificadores]
business.industry
Surrogate endpoint
Ribavirin
Hazard ratio
diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Original Articles
Hepatitis C
Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
medicine.disease
Cryoglobulinemia
Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]
chemistry
Nephrology
acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]
Virus de l'hepatitis C
Malalties del ronyó
030211 gastroenterology & hepatology
business
Cohort study
- Language
Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04–0.40]; P Conclusions Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.